Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
Oncology Times - OncTimes Talk
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
Author
Oncology Times
Published
Tue 11 Jun 2024
Episode Link
https://traffic.libsyn.com/secure/otbroadcastsarchives/OT_POD_EP88_061024.mp3.mp3
Share to:
